Pfizer settles Protonix patent case for $2.15B

Two generic drugmakers will pay $2.15 billion to Pfizer and Takeda Pharmaceutical to settle a patent fight over the heartburn treatment Protonix.

Teva Pharmaceutical Industries Ltd., one of the world's largest generic drugmakers, will pay $1.6 billion, while India's Sun Pharmaceutical Industries Ltd. will pay $550 million for selling their versions of Protonix before the protecting the drug expired.

., based in New York, said Wednesday that it will receive 64 percent of the settlement proceeds.

A jury had decided in 2010 that the patent protecting Protonix was valid, and the U.S. District Court for the District of New Jersey then upheld that decision. The companies reached their settlement shortly after the start of a federal trial to determine damages.

Its lawsuit aimed to recover some of the money lost after Protonix started competing with cheaper . Drugmaker Nycomed had developed Protonix before that company was purchased by Japan's Takeda Pharmaceutical Co. Nycomed had licensed Protonix to Wyeth, which has since purchased.

Nycomed had said U.S. sales for the drug reached $1.9 billion in 2007 but tumbled significantly afterward.

Teva had started selling its of Protonix in December 2007. Sun then launched its own version in early 2008 before the drug's U.S. patent expired in 2011.

Teva and Sun had used a tactic called an "at-risk ," meaning they started selling their versions before the patents on the original expired. They hoped to either get the patents overturned in court or reach a settlement that would allow them to start selling their products before the patents ran out.

Teva, based in Israel, said it expects to incur a second-quarter charge of about $930 million tied to the settlement.

Shares of Pfizer rose 34 cents to $28.76 in Wednesday morning trading, while U.S.-traded shares of Teva fell 27 cents to $39.56.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Pfizer painkiller gets longer patent protection (Update)

Mar 05, 2013

Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

Canada high court voids Pfizer's Viagra patent

Nov 08, 2012

Canada's top court on Thursday stripped Pfizer of its patent for Viagra, saying the pharmaceutical giant failed in the patent to identify the active compound in the drug.

Retailers sue Pfizer, charge generic Lipitor delay

Jul 07, 2012

(AP) — Five large U.S. drug and grocery chains are suing Pfizer Inc. and a second drugmaker, alleging they conspired to delay sales of cheap generic versions of the blockbuster cholesterol drug Lipitor.

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Court: Can drug companies pay to delay generics?

Mar 24, 2013

(AP)—Federal regulators are pressing the Supreme Court to stop big pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs. They argue ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments